[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abdominal-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abdominal-obesity":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,45,96,134,163,193,217,244,272,295,322,345,377,398],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100558714","phase-2-tesamorelin-as-an-adjunct-to-exercise-for-improving-physical-function-in-hiv-100558714",false,"NCT06554717","Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV","TRIUMPH","Inclusion Criteria:\n\n1. Men and women, 50-80 years old\n2. Documented HIV infection on suppressive antiretroviral therapy for at least 1 year with HIV-1 RNA \\\u003C200 copies\u002FmL and CD4+ T cell count \\>200\u002FµL 3\n3. Sedentary lifestyle, defined as self-reported physical activity that breaks a sweat \\\u003C3 days\u002Fweek with no regular resistance exercise in the past 3 months\n4. ≥1 Fried frailty criterion (weakness, slow gait speed, exhaustion, decreased physical activity, or unintentional weight loss as defined by specific thresholds)\n5. Excess abdominal adiposity as indicated by at least one of the following elevated anthropometric measures assessed at Screen: (1) waist circumference ≥102 cm in non-Asian males (≥90 cm in Asian males) or ≥88 cm in non-Asian females (≥80 cm in Asian females); (2) waist-to-hip ratio ≥0.9 in males or ≥0.85 in females; (3) waist-to-height ratio ≥0.5 in males and females\n6. Normal mammogram within 2 years (females ≤74 years old) or prostate specific antigen \\\u003C4 ng\u002FmL (males ≤70 years old) per U.S. Preventive Services Task Force (USPSTF) age-appropriate cancer screening guidelines\n7. For females, postmenopausal defined as no menses for ≥12 months and anti-müllerian hormone (AMH) \\\u003C20 pg\u002FmL or history of bilateral oophorectomy at least 3 months ago\n8. Provider approval to participate\n\nExclusion Criteria:\n\n1. Use of tesamorelin or other growth hormone (GH)-based therapy within 6 months\n2. Insulin-like growth factor 1 (IGF-1) z-score \\>2.0\n3. HbA1c \\>8%\n4. Active or suspected malignancy (with the exception of non-melanoma skin cancer) within 24 months\n5. Supraphysiologic testosterone or corticosteroid exposure, or change in exogenous testosterone or corticosteroid dose within 3 months\n6. Change in glucose-lowering medication (e.g., glucagon-like peptide-1 receptor agonists) within 3 months\n7. Active or unstable coronary artery disease, chest pain suspicious for angina, or serious arrythmia\n8. History of hypopituitarism, head irradiation, or other conditions known to affect the GH\u002FIGF-1 axis\n9. Known hypersensitivity to tesamorelin or mannitol\n10. Acute or chronic illness judged by the investigator to represent a contraindication to study participation","ALL","50 Years","80 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term.\n\nThe goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated.\n\nDuring a 24-week intervention phase, half of participants will be randomly assigned to receive tesamorelin and half of participants will be randomly assigned to receive placebo (a look-alike substance that contains no drug). All participants also will engage in a home-based exercise intervention supervised by an exercise coach. During a subsequent 24-week extension phase, individuals will be monitored off study drug and supervised exercise, and be encouraged to continue to exercise independently.\n\nThe investigators will investigate effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. They also will evaluate whether effects of tesamorelin are maintained following treatment cessation. This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations.",[27,28,29,30,31],"HIV-1-infection","Frailty","Impaired Physical Function","Abdominal Obesity","Aging","RECRUITING","2026-05-15",{"date":35,"type":36},"2026-05-19","ACTUAL",{"date":38,"type":36},"2025-07-10",{"date":40,"type":21},"2028-12-01",{"name":42,"class":43},"Massachusetts General Hospital","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":70,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100625406","long-term-effects-of-walnut-consumption-on-brain-function-100625406","NCT07422220","Long-Term Effects of Walnut Consumption on Brain Function","Long-Term Effects of Walnut Consumption on Brain Function in Men and Women With Abdominal Obesity","WalBrain","Inclusion Criteria:\n\n* Men and women, aged between 45-75 years\n* Women postmenopausal: two or more years after last menstruation\n* Waist circumference of ≥102 cm for men and ≥88 cm for women (abdominal obesity)\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study\n* No difficult venipuncture as evidenced during the screening visit\n\nExclusion Criteria:\n\n* Allergy or intolerance to walnuts\n* Left-handedness (effects on brain function differ between left- and right-handed adults)\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements (e.g., dietary fiber or antioxidant dietary supplements (vitamin C and E), fish or seaweed oil capsules) known to interfere with the main outcomes as judged by the principal investigators\n* Use of medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)",true,"45 Years","75 Years",{"count":57,"type":21},55,[59],"NA","Rationale: Healthy foods, including mixed nuts, may improve brain function, which is essential for cognitive and metabolic health, and may contribute to improved food intake regulation. It is therefore important to investigate the specific effects of walnuts on cerebral blood flow responses before and after intranasal insulin administration, as well as their associated functional benefits. The investigators hypothesize that long-term walnut consumption improves vascular function and insulin-sensitivity in the brain, thereby enhancing cognitive performance and appetite control in abdominally obese men and women. Objective: The primary objectives are to investigate in abdominally obese adults the effects of 24-week walnut consumption on (regional) vascular function and insulin-sensitivity in the brain, while the investigators will also assess changes in cognitive performance and appetite-related brain reward activity (secondary objectives). Cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin spray (brain insulin-sensitivity) will be quantified by the non-invasive gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labeling (ASL). Study design: This intervention study will have a randomized, controlled parallel design. The total study duration will be 24 weeks. Study population: Fifty-five abdominally obese men and (postmenopausal) women (aged 45-75 years) without a history of cardiovascular diseases or complaints will participate. This study population is expected to have a decreased cerebral blood flow at baseline and are also at increased risk of cognitive impairment, allowing for improvement by the intervention. Intervention: Study participants will receive daily 50 g (about 15% of energy) of raw walnuts (walnut intervention) or no walnuts (control intervention) for 24 weeks. Main study parameters\u002Fendpoints: At baseline and after 24 weeks (follow-up), participants will visit the research facilities for assessments. The primary endpoint is the difference in the cerebral blood flow response before and after intranasal insulin administration between the walnut and control intervention. Cognitive performance will be assessed, while the investigators will also focus on appetite-related brain reward activity (secondary outcomes).",[62,63,64,65,66,67,68,30,69],"Healthy","Brain Insulin Sensitivity","Cerebral Blood Flow","Brain Vascular Function","Satiety and Food Intake","Food Reward","Cognitive Performance","Cognitive Decline",[71,72,73,74,75,76,77,78,79,80,81,82,83,84],"Walnuts","Juglans","Brain vascular function","Brain insulin sensitivity","Satiety","Food reward mechanisms","Cognitive performance","Abdominal obesity","Cognitive decline","pCASL MRI","fMRI","CANTAB","Intranasal insulin","Food cues","NOT_YET_RECRUITING","2026-02-18",{"date":88,"type":36},"2026-02-19",{"date":90,"type":21},"2026-02",{"date":92,"type":21},"2027-08",{"name":94,"class":43},"Maastricht University Medical Center",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":95},"100622407","effect-of-electrical-stimulation-and-exercise-on-blood-flow-in-patients-with-resistant-high-blood-pressure-100622407","NCT07383220","Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure","Effect of Combined Transcutaneous Electrical Stimulation and Isometric Exercise on Peripheral Hemodynamic Parameters in Patients With Resistant Hypertension","Inclusion Criteria:\n\n* Age between 50 and 60 years. Both sexes were included Patients had been diagnosed with hypertension for at least 5 years.\n\nPatients had resistant hypertension according to (Whelton et al 2018), defined as:\n\n* Systolic blood pressure (SBP) ≥140 mmHg and\u002For diastolic blood pressure (DBP) ≥90 mmHg despite the use of three or more antihypertensive medications of different classes, including a diuretic,\n* or controlled blood pressure (\\\u003C140\u002F90 mmHg) while on four or more antihypertensive medications.\n\nBody Mass Index (BMI) 25: 34.9 kg\u002Fm²\n\nIncreased waist circumference, defined as:\n\n* Greater than 102 cm for males.\n* Greater than 88 cm for females.\n\nExclusion Criteria:\n\n* Secondary hypertension due to identifiable causes (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma).\n* History of major cardiovascular events in the last 6 months (e.g., myocardial infarction, stroke, or heart failure exacerbation).\n* Severe musculoskeletal or neurological disorders that impair the ability to perform isometric exercise safely (e.g., recent joint replacement, severe osteoarthritis, stroke with residual motor deficit).\n* Contraindications to the use of Transcutaneous Electrical Nerve Stimulation (TENS):\n\nImplanted electronic devices: pacemakers, cardioverter defibrillators. Uncontrolled arrhythmias. Sever skin condition: open wounds, rashes, burns, eczema. Peripheral neuropathy or sensory loss.\n\n-Known cognitive impairment or psychiatric conditions that would limit the ability to follow instructions or provide informed consent.","60 Years",{"count":105,"type":21},50,[59],"The goal of this clinical trial is to learn if the combination between transcutaneous electrical nerve stimulation (TENS) and isometric exercise (IE) can improve blood pressure in men and women between 50 to 60 years old suffered from resistant hypertension which is a type of hypertension where blood pressure remains above your target goal despite the use of three or more different classes of antihypertensive medications at their maximum tolerated doses. The main question to answer is:\n\nIs there a significant effect on the combined use of TENS and IE on peripheral hemodynamic parameters in patients with resistant hypertension? Total sample will be 50 patients from both sexes\n\nI will compare between two groups:\n\nExperimental group (15 men, 10 women) will take: medication plus IE and TENS Control group (15 men, 10 women) will take: medication plus Conventional Physical Therapy Program",[109,110,111,30,112,113,114,115],"Resistant Hypertension","Hemodynamic Instability","Essential (Primary) Hypertension","Metabolic Syndrome","Hypertension (HTN)","Vascular Resistance","High Blood Pressure",[117,118,119,120,121,122,123,124],"Mean Arterial Pressure","Peripheral Hemodynamics","Physical Therapy","Long Term Hypertension","Resistant HTN","Systolic Blood Pressure (SBP)","Diastolic Blood Pressure (DBP)","Heart Rate Variability (HRV)","2026-01-28",{"date":127,"type":36},"2026-02-03",{"date":129,"type":21},"2026-01-15",{"date":131,"type":21},"2026-06-10",{"name":133,"class":43},"Mohamed Mohamed Ali Morgan",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":53,"sex":142,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":95},"100600033","evaluation-of-exercise-capacity-in-teenage-females-using-virtual-reality-and-plyometric-workout-100600033","NCT07092228","Evaluation of Exercise Capacity in Teenage Females Using Virtual Reality and Plyometric Workout","Evaluation of Exercise Capacity in Teenage Females With Abdominal Obesity Using Virtual Reality and Plyometric Workout: Randomized Clinical Trial","VR","Inclusion Criteria:\n\n* Body mass index more than or equal to 30 Kg\u002Fcm2\n* waist circumference more than 80 cm\n* medical history of polycystic ovarian syndrome\n* Age from 13 to 18 years\n\nExclusion Criteria:\n\n* uncontrolled hypertension\n* Rheumatoid arthritis\n* Any respiratory diseases like Asthma and respiratory infections\n* Osteoprosis","FEMALE","13 Years","18 Years",{"count":20,"type":21},[59],"to evaluate the efficacy of virtual reality combined with plyometric workout on abdominal obesity in adolescent females",[30],[150,151,152,153],"virtual reality","plyometric exercises","abdominal obesity","exercise capacity","2025-12-02",{"date":156,"type":36},"2025-12-03",{"date":158,"type":36},"2025-06-20",{"date":160,"type":21},"2026-01-01",{"name":162,"class":43},"New Ismailia National University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":4},"100606817","effectiveness-of-whole-body-vibration-on-health-outcomes-in-older-adults-with-dynapenic-abdominal-obesity-100606817","NCT07180485","Effectiveness of Whole Body Vibration on Health Outcomes in Older Adults With Dynapenic Abdominal Obesity","The Effectiveness of Whole Body Vibration Training in Improving Brain Activity, Bone Mineral Density, Quality of Life, and Biomarkers for the Older People With Dynapenic Abdominal Obesity","Inclusion Criteria:\n\nOutpatients aged 65 years or older\n\nDiagnosed with dynapenic abdominal obesity\n\nAble to understand and follow simple instructions\n\nAble to communicate clearly and express their own will\n\nWilling to sign the informed consent form\n\nExclusion Criteria:\n\nInability to communicate in Mandarin or Taiwanese, resulting in inability to participate in research activities\n\nSevere visual or hearing impairment that hinders study participation\n\nPresence of cognitive impairment, musculoskeletal or severe osteoporosis-related conditions\n\nRefusal to sign the informed consent form","65 Years","100 Years",{"count":173,"type":21},120,[59],"This study focuses on whole body vibration training (WBVT), a form of neuromuscular training that uses mechanical vibrations. WBVT has been shown to improve muscle function, bone mineral density, and quality of life. While some benefits have been observed in the elderly population, there remains a research gap concerning its effectiveness in older adults with dynapenic abdominal obesity. Therefore, the findings of this study will provide new evidence for health interventions targeting this specific group.\n\nThis research targets outpatients aged 65 and above who meet the criteria for dynapenic abdominal obesity. It aims to evaluate the effects of WBVT on brain activity, osteoporosis, quality of life, and biological markers. The study period is from February 1, 2025, to January 31, 2027, with a planned sample size of 120 participants, equally divided into an experimental group and a control group (60 participants each).",[177,30],"Dynapenia",[179,180,181,182,183],"whole-body vibration training","brain activity","bone mineral density","quality of life","biomarkers","2025-09-16",{"date":186,"type":36},"2025-09-18",{"date":188,"type":21},"2025-10-01",{"date":190,"type":21},"2027-10-01",{"name":192,"class":43},"Dalin Tzu Chi General Hospital",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":144,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":95},"100372999","influence-of-freeo2-on-percentage-of-time-within-oxygen-saturation-target-using-noninvasive-ventilation-niv-and-continuous-positive-airway-pressure-cpap-for-patients-admitted-for-aecopd-or-bariatric-surgery-100372999","NCT04136717","Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery","Influence of Automatic Oxygen Titration Device (FreeO2) on Percentage of Time Within Oxygen Saturation Target and Induced Hypercapnia During Noninvasive Ventilation for Patients Hospitalized for an Acute Exacerbation of COPD or a Bariatric Surgery","Inclusion Criteria (AECOPD):\n\n* Respiratory acidosis (pH \\\u003C= 7.35 and PaCO2 \\> 45 mmHg), with or without NIV (last blood gas available during hospitalization)\n* Oxygen therapy and\u002For SpO2 \\\u003C90% room air (FiO2 \\\u003C= 50% or nasal cannula \\\u003C= 7 L\u002Fmin to maintain SpO2 90%)\n* High flow nasal cannula with flow \\\u003C= 30 L\u002Fmin\n\nInclusion Criteria (Bariatric surgery post-op):\n\n* Patients using CPAP before the surgery (obstructive sleep apnea documented).\n* Patients with obesity hypoventilation syndrome in addition to obstructive sleep apnea can be included.\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Pregnancy\n* Respiratory distress or other clinical situation requiring continuous NIV or CPAP\n* Glasgow \\\u003C 12 or agitation\u002Fdelirium\u002Fdementia (limiting NIV)\n* Any contraindication to NIV (state requiring immediate endotracheal intubation, pneumothorax, recent esophagus surgery)\n* Hemodynamic instability (at the beginning of the study) (increasing doses of vasopressors or inotropes)\n* Refusal to consent to the study\n\n  5 patient with AECOPD and 5 patient with bariatric surgery will be included.",{"count":201,"type":21},10,[59],"The main objective is to evaluate the FreeO2 device combined with noninvasive respiratory support technique for COPD patients and postoperative bariatric surgery patients.\n\nThe main hypothesis is that FreeO2 device for oxygen therapy associated with NIV or nasal high flow oxygen therapy (NHFOT) allows to reach better oxygenation and avoid hypoxemia and hyperoxia.",[205,206,30,207],"COPD Exacerbation","Oxygen Toxicity","Surgery","2025-08-27",{"date":210,"type":36},"2025-09-04",{"date":212,"type":36},"2019-10-28",{"date":214,"type":21},"2028-06",{"name":216,"class":43},"François Lellouche",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":144,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":232,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":95},"100543711","acupuncture-for-prediabetes-with-combined-obesity-100543711","NCT06359418","Acupuncture for Prediabetes With Combined Obesity","Acupuncture for Prediabetes With Combined Obesity: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n\\-\n\nSubjects are eligible to be included in the trial only if all of the following criteria apply:\n\n1. Simultaneously meeting the diagnostic criteria for both general obesity, abdominal obesity, and prediabetes;\n2. Aged 18-64 years old;\n3. Informed consent obtained before any trial-related activities.\n\nExclusion Criteria:\n\n\\-\n\nSubjects are excluded from the trial if any of the following criteria apply:\n\n1. Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established Polycystic Ovary Syndrome);\n2. impaired glucose regulation due to hyperthyroidism, endocrine tumors and extensive liver damage;\n3. Diagnosis of type 1 or type 2 diabetes per the judgment of the investigator;\n4. Current or history of treatment with medications that may cause significant weight gain, within 3 months prior to screening, including systemic corticosteroids (except for a short course of treatment, i.e. 7-10 days), antidepressants, antipsychotic, mood stabilizers, antiepileptic and hormone contraceptive;\n5. History of pancreatitis or pancreatectomy;\n6. Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device;\n7. Current participation (or within the last month) in an organized weight reduction program or currently using or used medication for obesity or hyperglycemia within 3 months before screening: liraglutide, exenatide, pramlintide, orlistat, topiramate, phenteremine, or metformin (either by prescription or as part of a clinical trial);\n8. A self-reported change in body weight \\>5 kg within 3 months before screening irrespective of medical records;\n9. Serious medical conditions (including but not limited to ongoing renal or hepatic insufficiency, congestive heart failure, myocardial infarction, stroke, hematopoietic system diseases, progressive malignant tumor or other serious consumptive diseases); history of angina pectoris, transient ischemic attack, claudication, or acute limb ischemia within the past 6 months prior to screening;\n10. Serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder, (e.g. borderline or antisocial), current severe major depressive disorder, recent (previous 6 months) suicide attempt or current active suicidal ideation, recent hospitalization due to psychiatric illness;\n11. Skin infection, blood coagulation disorders and other conditions that are not suitable for acupuncture;\n12. Metal allergies or severe fear of needles;\n13. Pregnant or breast-feeding women or planning to become pregnant during the study period;\n14. Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.","64 Years",{"count":226,"type":21},260,[59],"The clinical trial aims to evaluate the efficacy and safety of acupuncture in reducing weight and waist circumference while modulating glucose and lipid metabolism in Prediabetes with Combined Obesity.",[230,30,231],"Obesity","PreDiabetes",[233,234,230,30,231],"acupuncture","randomized controlled trial","2025-08-16",{"date":237,"type":36},"2025-08-22",{"date":239,"type":36},"2025-03-01",{"date":241,"type":21},"2028-04-01",{"name":243,"class":43},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":53,"sex":16,"minAge":252,"maxAge":170,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":95},"100513200","culturally-adapted-dietary-clinical-trial-in-pr-100513200","NCT05962372","Culturally Adapted Dietary Clinical Trial in PR","Culturally Adapted Dietary Clinical Trial in PR: Puerto Rico Evaluation of a Culturally Informed Sustainable Intervention for Optimal Nutrition (PRECISION)","PRECISION","Inclusion Criteria:\n\n1. Age 30-65y old at the time of enrollment\n2. Non-institutionalized\n3. Living in PR at the time of recruitment and for at least the previous year and not planning to move from the island within the next 3 years\n4. Able to answer questions without assistance\n5. Having a cellphone with the capacity to receive text messages and be willing to receive daily text messages from the study on the designated cellphone number\n6. Having at least one of the following:\n\n   1. elevated BMI\n   2. elevated waist circumference\n   3. self-reported physician-diagnosed hypertension or use of hypertension medication or measured high blood pressure at the baseline visit\n   4. self-reported physician-diagnosed pre-diabetes or measured pre-diabetes at the baseline visit\n   5. self-reported physician-diagnosed dyslipidemia or use of lipid-lowering agents or laboratory values confirming dyslipidemia\n\nExclusion Criteria:\n\n1. Under 30 or over 65 years of age (on the day of the interview).\n2. Currently not living in Puerto Rico or not lived on the island for at least 1 year or planning to move within 3 years\n3. Institutionalized\n4. Not able to answer questions without assistance\n5. Not having at least 1 of the five listed metabolic criteria\n6. Self-reported physician-diagnosed type 1 or type 2 diabetes or use of diabetes medication (including insulin) or diabetes-diagnosis values confirmed by laboratory\n7. Self-reported pregnancy\n8. Gastrointestinal or chronic condition that would impact eating behaviors or nutritional status\n9. Intolerance or allergies to legumes (i.e.: beans and nuts), vegetable oils (i.e.: corn, olive, canola), or fresh produce\n10. Living with another person participating in the study\n11. Participating in another research study that conflicts with PRECISION","30 Years",{"count":254,"type":21},250,[59],"This project will determine whether a diet culturally adapted to adults in Puerto Rico can effectively decrease cardiometabolic risk factors. This will help define a culturally-appropriate, feasible, and sustainable diet intervention aimed at reducing cardiovascular, type 2 diabetes, and obesity outcomes.",[258,230,259,260,261,262,30],"Diabetes Mellitus, Type 2","Hypertension","Dyslipidemias","High Triglycerides","High Blood Glucose","2025-07-29",{"date":265,"type":36},"2025-07-31",{"date":267,"type":36},"2024-05-02",{"date":269,"type":21},"2029-05-02",{"name":271,"class":43},"Harvard School of Public Health (HSPH)",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":53,"sex":279,"minAge":144,"maxAge":18,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":95},"100434729","translational-study-using-human-abdominal-adipose-tissue-biopsies-to-investigate-the-role-of-cannabinoid-receptor-1-cb1-in-controlling-endocannabinoid-and-adipokine-secretion-100434729","NCT04940962","Translational Study Using Human Abdominal Adipose Tissue Biopsies to Investigate the Role of Cannabinoid Receptor 1 (CB1) in Controlling Endocannabinoid and Adipokine Secretion","ENDOCATA","Inclusion Criteria:\n\n* Controls:\n* men or post-menopausal women aged between 18 and 80\n* gave oral consent\n* to undergo visceral surgery\n\nNon-diabetic obese subjects:\n\n* men or post-menopausal women aged between 18 and 80\n* BMI \\> 30\n* gave oral consent\n* to undergo visceral surgery\n\nObese diabetic subjects:\n\n* men or post-menopausal women aged between 18 and 80\n* type 2 diabetic not treated with Insulin or GLP-1 agonist\n* BMI \\> 30\n* gave oral consent\n* to undergo visceral surgery\n\nExclusion Criteria:\n\n* Controls:\n* Person not covered by national health insurance.\n* BMI \\> 30\n* diabetes\n* chronic inflammatory disease\n* cancer undergoing chemotherapy or chemotherapy less than a year old\n* digestive cancer with recent weight loss (≥10%) and\u002For malnutrition\n* known metastatic cancer\n* cancer undergoing long-term hormonal treatment\n* protected adult\n\nNon-diabetic obese subjects:\n\n* Person not covered by national health insurance\n* diabetes\n* chronic inflammatory disease\n* cancer undergoing chemotherapy or chemotherapy less than a year old\n* digestive cancer with recent weight loss (≥10%) and\u002For malnutrition\n* known metastatic cancer\n* cancer undergoing long-term hormonal treatment\n* protected adult\n\nObese diabetic subjects:\n\n* Person not covered by national health insurance\n* chronic inflammatory disease\n* cancer undergoing chemotherapy or chemotherapy less than a year old\n* digestive cancer with recent weight loss (≥10%) and\u002For malnutrition\n* known metastatic cancer\n* cancer undergoing long-term hormonal treatment\n* type 1 diabetes\n* secondary diabetes\n* protected adult","MALE",{"count":281,"type":21},45,[59],"Abdominal obesity and type 2 diabetes are associated with the hyperactivation of the endocannabinoid system. Several animal and human studies indicate that circulating endocannabinoid (EC) levels are correlated with body fat. Thus, adipose tissue, which possesses the enzymatic machinery for the synthesis of ECs, could be the main producer of plasma ECs.\n\nToday, it is clearly established that stimulation of the endocannabinoid system, via activation of cannabinoid receptor 1 (CB1s) located in the brain, leads to increased food intake and weight gain. Moreover, peripheral CB1s present in organs such as the liver, muscles and adipose tissue are involved in the establishment of metabolic deregulations linked to obesity (steatosis, insulin resistance, dyslipidemia).\n\nThus, ECs produced by adipose tissue could play a key role in the regulation of carbohydrate-lipid homeostasis through their autocrine or paracrine actions by activating central and peripheral CB1s. Therefore, the objective of this study is to:\n\n1. clarify whether obesity, associated or not with diabetes, leads to an overproduction of ECs (specifying which ones) by visceral or subcutaneous adipose tissue\n2. to determine whether blocking CB1s with new peripherally acting antagonists can lead to a reduction in the production of ECs by adipose tissue.\n\nThis study will also provide an opportunity to evaluate the production of adipokines and cytokines involved in the control of energy homeostasis under the different experimental conditions.",[285,30],"Diabete Type 2","2025-07-24",{"date":288,"type":36},"2025-07-28",{"date":290,"type":36},"2021-09-29",{"date":292,"type":21},"2027-09",{"name":294,"class":43},"Centre Hospitalier Universitaire Dijon",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":144,"maxAge":170,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":309,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":95},"100585052","transversus-abdominis-plan-block-versus-rectus-sheath-block-100585052","NCT06897345","Transversus Abdominis Plan Block Versus Rectus Sheath Block","Comparison of Postoperative Analgesic Efficacy of Transversus Abdominis Plan Block and Rectus Sheath Block in Abdominoplasty Cases: A Randomized Prospective Clinical Trial","Inclusion Criteria:\n\nPatients who will undergo elective abdominoplasty\n\n* Patients between the ages of 18-65\n* ASA (American Society of Anesthesiologists) I-II-III patients\n* Patients with a body weight between 50-80 kg\n\nExclusion Criteria:\n\n* \\- ASA IV patient group\n* Patients under 18 years of age\n* Patients without cooperation\n* Patients with chronic alcohol use\n* Patients in whom peripheral plane block application is contraindicated (infection at the application site, coagulopathy, local anesthetic allergy)\n* Patients who do not want to participate in the study",{"count":303,"type":21},60,[59],"The investigator aims to compare the analgesic efficacy of Transversus Abdominis Plan Block and Rectus Sheath Block which are used to prevent intraoperative and postoperative pain and reduce the use of opioid in abdominoplasty operations.",[30,307,308],"Postoperative Pain","Postoperative Complications",[310,311,312],"post operative pain","transversus abdominis plane block","rectus sheat block","2025-03-20",{"date":315,"type":36},"2025-03-26",{"date":317,"type":21},"2025-05-01",{"date":319,"type":21},"2025-12-01",{"name":321,"class":43},"Sisli Hamidiye Etfal Training and Research Hospital",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":53,"sex":16,"minAge":252,"maxAge":170,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":341,"leadSponsor":343,"locationsCount":95},"100581202","innuprec-nutrigenetic-intervention-for-the-prevention-of-cardiovascular-disease-100581202","NCT06847243","INNUPREC (Nutrigenetic Intervention for the Prevention of Cardiovascular Disease)","Effect of Nutrigenetic Intervention on Cardiovascular Biomarkers, Oxidative Stress and Antioxidant Capacity in Subjects with Abdominal Obesity","INNUPREC","Inclusion Criteria:\n\n* 30-65 years of age\n* Subjects who agree to participate in the study and all signed informed consent\n* Women with a waist circumference ≥ 88 cm and men ≥ 102 cm according to NCEP\u002FATPIII.\n\nExclusion Criteria:\n\n* Currently consuming any of the following drugs: NSAIDs, anticoagulants, hypoglycemic, or hypolipemic drugs\n* Diagnosed autoimmune diseases\n* Diagnosed cancer\n* Pregnancy and breastfeeding\n* Subjects who have undergone a dietary intervention at the time or up to 3 months prior\n* Subjects who wish to abandon the study",{"count":303,"type":21},[59],"Background: Abdominal obesity (AO) is a multifactorial disease that affects 81.6% of the Mexican population; it is characterized by the excessive accumulation of adipose tissue in abdominal region. Scientific evidence suggest that regional fat distribution plays a critical role in the development of cardiovascular diseases (CVD). The main processes involved in the increased risk of developing CVD in the presence of AO are alterations in insulin signaling, dyslipidemias, atherosclerosis, inflammation, and oxidative damage. On the last years has been reported genetic variations associated with AO and dyslipidemia. In addition, interactions have been found between these genetic variants and diet that may be influencing a differential response in metabolic, molecular, and phenotypic processes, which favor the development of CVD. Objective: Evaluate the effect of nutrigenetic intervention on cardiovascular biomarkers, oxidative stress and antioxidant capacity in subjects with abdominal obesity. Materials and methods: The present study is a simple randomized clinical trial. Participants will be randomized into one of two groups of intervention; Control group and Nutrigenetic group during a 2-month follow-up period. Anthropometric, dietary evaluation and biochemical markers assessments will be monitored at baseline, at 4 weeks (mid-intervention), and at 8 weeks (end of intervention). The dietary evaluation was analyzed by Nutritionist Pro software. Body composition was evaluated by electrical bioimpedance (InBody 370). All biochemical determinations were analyzed by dry chemistry (Vitros 350) and cardiometabolic markers by colorimetric immunoassay technology. Infrastructure: Institute of Translational Nutrigenomics and Nutrigenomics, University Center for Health Sciences, University of Guadalajara.",[30],[78,335,336],"Nutrigenetic intervention","Cardiometabolic biomarkers","2025-02-26",{"date":339,"type":36},"2025-03-03",{"date":239,"type":21},{"date":342,"type":21},"2025-09-01",{"name":344,"class":43},"University of Guadalajara",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":53,"sex":16,"minAge":144,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":364,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":95},"100558748","exploring-physical-exercise-for-the-regulation-and-control-of-metabolic-disorders-in-college-students-100558748","NCT06555159","Exploring Physical Exercise for the Regulation and Control of Metabolic Disorders in College Students.","EFFECT OF AN AEROBIC EXERCISE PROGRAM ON METABOLIC DISORDERS LEVELS IN HIGHER EDUCATION STUDENTS AT THE UNIVERSITY OF COLIMA, RANDOMIZED CLINICAL TRIAL.","(EPE_RCTMCS)","Inclusion Criteria:\n\n* University of Colima students linked to the central campus.\n* Students aged between 18 and 25 years old.\n* Authorization to participate in the project with a signed informed consent.\n* Suffer from at least one of the parameters of metabolic disorders or cardiovascular risk (Hyperglycemia, decreased DHL, elevated triglycerides, abdominal obesity or hypertension) following the clinical assessment (Considering the criteria established by the ADA and ATPIII).\n\nExclusion Criteria:\n\n* Motor limitations that may hinder the performance of physical exercise.\n* Pregnancy or lactation.\n* High Vigorous Physical Activity Level according to the IPA-Q.\n* To be currently under pharmacological treatment to manage altered metabolic levels.\n\nELIMINATION CRITERIA\n\n* Musculoskeletal injuries during the study period.\n* Unforeseen Medical Events: Unexpected medical situations that could influence study results, such as hospitalizations, serious illnesses, or surgeries.\n* Non-Compliance with Follow-Up: Subjects failing to meet a minimum of 80% (19 out of 24 sessions) of the stipulated physical conditioning program time.\n* Initiation of clinical treatment that may affect protocol results, such as medications that reduce alterations.\n* Participants who voluntarily withdraw from the study.","25 Years",{"count":355,"type":21},48,[59],"This clinical trial objective is to evaluate the effect of an aerobic physical exercise program on reducing triglycerides, blood pressure, abdominal obesity, altered glucose levels, and the increase in HDL in college-level students at the University of Colima. It will try to answer whether aerobic physical exercise reduces metabolic disorders (altered blood pressure and glucose levels, abdominal obesity, and increased HDL). A simple randomized clinical trial will be conducted with a sample of 48 voluntary students from the University of Colima, divided into two groups of 24 people (Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax; and Experimental Group -B-, will undergo an aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload).\n\nResearchers will compare the results of both groups to confirm the effectiveness of the planned aerobic physical exercise in reducing these risks.",[359,30,360,361,362,363],"Metabolic Disorders","Blood Pressure Disorders","Hypertriglyceridemia","Hyperglycemia","HDL-Deficiency",[365,230,366,367,259],"Exercise","HDL","Triglycerides","2024-08-12",{"date":370,"type":36},"2024-08-15",{"date":372,"type":21},"2024-09",{"date":374,"type":21},"2025-06",{"name":376,"class":43},"Universidad de Colima",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":53,"sex":142,"minAge":384,"maxAge":353,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":4},"100556753","effect-of-ultrasound-cavitation-versus-whole-body-vibration-on-abdominal-fat-in-obese-adolescent-females-100556753","NCT06529211","Effect of Ultrasound Cavitation Versus Whole Body Vibration on Abdominal Fat in Obese Adolescent Females","Effect of Ultrasound Cavitation Versus Whole Body Vibration on Abdominal Fat in Obese Adolescent Females: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Adolescent females suffer from abdominal obesity.\n* Their ages will be ranged from 17 to 25 years old.\n* Their body mass index (BMI) will be ranged from 30 to 35 kg\u002Fm2.\n* Their waist circumference will be \\> 88 cm.\n* Their WHR will be more than 0.88.\n\nExclusion Criteria:\n\nFemales will be excluded from the study if they have:\n\n* Thyroid, hepatic and kidney disorders.\n* Diabetes mellitus, coronary artery diseases, hypertension and congestive heart failure.\n* Recent abdominal surgical scar or umbilical hernia.\n* History of orthopedic implants insertion or cardiac pacemaker implantation.","17 Years",{"count":303,"type":21},[59],"This study aims to determine the differences between the effect of ultrasound cavitation and whole-body vibration on abdominal fat in obese adolescent females",[30],"2024-07-26",{"date":391,"type":36},"2024-07-31",{"date":393,"type":21},"2024-07-22",{"date":395,"type":21},"2024-12-10",{"name":397,"class":43},"Cairo University",{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":53,"sex":16,"minAge":144,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":409,"phases":4,"briefSummary":410,"conditions":411,"keywords":418,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":4},"100543413","individual-factors-related-to-chronic-low-grade-inflammation-and-cardiometabolic-disease-risk-100543413","NCT06355544","Individual Factors Related to Chronic Low-grade Inflammation and Cardiometabolic Disease Risk","Integrative and Personalized Lifestyle Approach to Reduce Low-Grade Inflammation in People at Risk of Cardiometabolic Diseases","PINEAPPL","Inclusion Criteria:\n\n* Male or female between the ages of 18 and 70 included,\n* One of the following two criteria:\n* Clinically at-risk group Body Mass Index between 25 (included) and up to 35 kg\u002Fm2 (excluded)\n* Non-clinically at-risk group Body Mass Index between 18.5 (included) and up to 25 kg\u002Fm2 (excluded) and absence of metabolic syndrome criteria\n* Subject covered by social security or a similar system.\n* Ability to use a mobile phone application on a daily basis (food intake).\n* Subject, after being informed of the contents of this study, fully understanding and accepting its purpose; and able to personally sign a written informed consent\n\nExclusion Criteria:\n\n* Subject with diagnosed inflammatory disease or infection-related inflammation (viral or bacterial) or medical history (viral) within the last 2 months:\n* Rheumatoid arthritis, reactive or psoriatic arthritis (non-osteoarthritis)\n* Inflammatory bowel disease (IBD) (Crohn\\'s disease or ulcerative colitis) or irritable bowel syndrome\n* Systemic lupus erythematosus\n* Uncontrolled psoriasis\n* Viral hepatitis or ongoing viral infection\n* Seasonal virus (influenza-like illness)\n* Subjects who have taken antibiotics in the last 2 months\n* Subject under treatment within the last 2 months of an:\n* Antiviral (for HIV, hepatitis, influenza, chickenpox\u002Fshingles)\n* Oral, topical, or injectable treatment of a drug that modulates the inflammatory response (e.g. Corticosteroid, non-steroidal anti-inflammatory drugs (e.g. ibuprofen, diclofenac, celecoxib, naproxen, aspirin, etc.)\n* Dietary supplement that can modulate the inflammatory response (e.g.\n* Omega 3 fatty acid, curcuma\u002Fturmeric, probiotic, prebiotics)\n* Subject with diabetes (type 1 or 2) known treated prior to the inclusion visit (specifically subjects recently diagnosed or diagnosed with diabetes at the time of the laboratory assessment may be retained in the study if they are not taking anti-diabetic treatment): i.e. exclusion of subject with diabetes diagnosed with fasting blood glucose ≥ 126 mg\u002FdL (7.0 mmol measured twice\u002FL OR glycated hemoglobin ≥ 6.5% (48 mmol\u002Fmol) AND anti-diabetic therapy (metformin, GLP-1 receptor agonist, insulin, sulphonylurea, alpha-glucosidase inhibitor)\n* Subject with severe or unstable hepatic, renal, cardiovascular, respiratory, endocrine, or metabolic disorders or cancer diagnosed with or without treatment\n* Subject suffering from gastrointestinal disorders resulting in the use of laxatives or drugs for intestinal transit (e.g., loperamide) in the last 2 months.\n* Subject with a complication or procedure in the last 2 months that could result in inflammation\n* Minor or acute tendonitis, sprain, or contusion\n* Severe contusion (e.g. Bone contusion)\n* Major or invasive surgery\n* Subject in a situation that, in the opinion of the investigator, could interfere with optimal participation in the present study or pose a particular risk to the subject.\n* Subject currently participating in an interventional clinical study\n* Subject not affiliated to the Social Security scheme\n* Subject who did not comply with the exclusion period of the study in which they would have previously participated\n* Subject not being able to use the internet","70 Years",{"count":408,"type":21},3000,"OBSERVATIONAL","The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.\n\nThe main questions it aims to answer are:\n\n* Whether it is possible to predict low-grade inflammation\n* What are the medical, biological, and lifestyle variables related to low-grade inflammation?\n\nParticipants will be asked to:\n\n1. Attend a general medical visit to collect vital signs, anthropometric measurements, and collect blood samples.\n2. Complete questionnaires and collect a stool sample at home.",[412,230,112,62,413,414,415,259,416,30,417],"Overweight","Low-grade Inflammation","Normal Weight Adults","Risk Factor, Cardiovascular","Hypercholesterolemia","Metabolically Healthy Controls",[419,420,421,422,423,424],"nutrition","microbiome","lifestyle factors","low-grade inflammation","personalized nutrition","precision nutrition","2024-04-04",{"date":427,"type":36},"2024-04-09",{"date":429,"type":21},"2024-04",{"date":431,"type":21},"2026-06-30",{"name":433,"class":434},"Integrative Phenomics","INDUSTRY"]